The center complements other NIH centers at SLAC and elsewhere that broaden access to this cutting-edge technology for biomedical research.

Images reveal how some antibodies may block SARS-CoV-2 infection.

Scientists at the Stanford Synchrotron Radiation Lightsource will study plastics and biologically-motivated processes that break them down in hopes of finding more efficient ways to “upcycle” them.

FACET-II will pave the way for a future generation of particle colliders and powerful light sources, opening avenues in high-energy physics, medicine, and materials, biological and energy science.

No human cell can function without these tiny machines, which cause disease when they go haywire and offer potential targets for therapeutic drugs.

They found that gently heating N95 masks in high relative humidity could inactivate SARS-CoV-2 virus trapped within the masks, without degrading the masks’ performance.

Using SLAC’s synchrotron, Summers improves fundamental knowledge of the role of copper in the brain and investigates treatments for Alzheimer’s disease.

University of Alberta researchers worked with SLAC X-ray scientists to explore the potential of a feline coronavirus drug that may be effective against SARS-CoV-2.

Chung is being recognized for pathbreaking contributions to the study of proteins involved in Parkinson’s and Alzheimer’s diseases and for mentoring the next generation of synchrotron scientists.

Stanford and SLAC scientists studying the varicella zoster virus found that an antibody that blocks infection doesn’t work exactly as they’d thought.

The technique they used will offer insight into many different chemical reactions.

Scientists are deploying this state-of-the-art X-ray crystallography facility to study biological molecules related to the COVID-19 pandemic.